» Articles » PMID: 35055050

Consequences of COVID-19 for the Pancreas

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Jan 21
PMID 35055050
Authors
Affiliations
Soon will be listed here.
Abstract

Although coronavirus disease 2019 (COVID-19)-related major health consequences involve the lungs, a growing body of evidence indicates that COVID-19 is not inert to the pancreas either. This review presents a summary of the molecular mechanisms involved in the development of pancreatic dysfunction during the course of COVID-19, the comparison of the effects of non-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on pancreatic function, and a summary of how drugs used in COVID-19 treatment may affect this organ. It appears that diabetes is not only a condition that predisposes a patient to suffer from more severe COVID-19, but it may also develop as a consequence of infection with this virus. Some SARS-CoV-2 inpatients experience acute pancreatitis due to direct infection of the tissue with the virus or due to systemic multiple organ dysfunction syndrome (MODS) accompanied by elevated levels of amylase and lipase. There are also reports that reveal a relationship between the development and treatment of pancreatic cancer and SARS-CoV-2 infection. It has been postulated that evaluation of pancreatic function should be increased in post-COVID-19 patients, both adults and children.

Citing Articles

Review of organ damage from COVID and Long COVID: a disease with a spectrum of pathology.

Ewing A, Salamon S, Pretorius E, Joffe D, Fox G, Bilodeau S Med Rev (2021). 2025; 5(1):66-75.

PMID: 39974559 PMC: 11834749. DOI: 10.1515/mr-2024-0030.


Hormonal Implications of SARS-CoV-2: A Review of Endocrine Disruptions.

Yskak A, Sokharev Y, Zhumalynov K, Koneva E, Afanasyeva N, Borodulin D Scientifica (Cairo). 2025; 2025():7305185.

PMID: 39830837 PMC: 11742418. DOI: 10.1155/sci5/7305185.


State of Knowledge About Thyroid Cancers in the Era of COVID-19-A Narrative Review.

Bronowicka-Szydelko A, Rabczynski M, Dumas I, Fiodorenko-Dumas Z, Wojtczak B, Kotyra L Biomedicines. 2025; 12(12.

PMID: 39767735 PMC: 11672969. DOI: 10.3390/biomedicines12122829.


Implications of Dysnatremia and Endocrine Disturbances in COVID-19 Patients.

Zlosa M, Grubisic B, Svitek L, Sabadi D, Canecki-Varzic S, Mihaljevic I Int J Mol Sci. 2024; 25(18).

PMID: 39337343 PMC: 11432667. DOI: 10.3390/ijms25189856.


Association of COVID-19 With Emergence of Comorbidities: A Hospital-Based Cohort Study.

Nayyar K, Sidhu T, Garg A Cureus. 2024; 16(8):e66147.

PMID: 39233974 PMC: 11372245. DOI: 10.7759/cureus.66147.


References
1.
Pan H, Peto R, Henao-Restrepo A, Preziosi M, Sathiyamoorthy V, Abdool Karim Q . Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2020; 384(6):497-511. PMC: 7727327. DOI: 10.1056/NEJMoa2023184. View

2.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

3.
Goyal H, Sachdeva S, Perisetti A, Mann R, Inamdar S, Tharian B . Hyperlipasemia and Potential Pancreatic Injury Patterns in COVID-19: A Marker of Severity or Innocent Bystander?. Gastroenterology. 2020; 160(3):946-948.e2. PMC: 7598680. DOI: 10.1053/j.gastro.2020.10.037. View

4.
Rahmani H, Davoudi-Monfared E, Nourian A, Khalili H, Hajizadeh N, Zarei Jalalabadi N . Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial. Int Immunopharmacol. 2020; 88:106903. PMC: 7445008. DOI: 10.1016/j.intimp.2020.106903. View

5.
Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y . Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020; 71(16):2027-2034. PMC: 7184337. DOI: 10.1093/cid/ciaa344. View